Edition:
United States

Heron Therapeutics Inc (HRTX.OQ)

HRTX.OQ on NASDAQ Stock Exchange Capital Market

15.40USD
14 Dec 2017
Change (% chg)

$-0.30 (-1.91%)
Prev Close
$15.70
Open
$15.85
Day's High
$15.93
Day's Low
$15.40
Volume
155,829
Avg. Vol
159,526
52-wk High
$18.35
52-wk Low
$12.25

Latest Key Developments (Source: Significant Developments)

Heron Therapeutics Announces Pricing Of Public Offering Of Common Stock
Tuesday, 5 Dec 2017 09:00am EST 

Dec 5 (Reuters) - Heron Therapeutics Inc ::HERON THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.HERON THERAPEUTICS INC - ‍PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF $150 MILLION OF SHARES OF ITS COMMON STOCK​.  Full Article

Heron Therapeutics Announces Public Offering Of Common Stock
Monday, 4 Dec 2017 04:01pm EST 

Dec 4 (Reuters) - Heron Therapeutics Inc ::HERON THERAPEUTICS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK.HERON THERAPEUTICS INC - INTENDS TO USE PROCEEDS FROM PROPOSED SALE OF ITS SHARES OF COMMON STOCK FOR GENERAL CORPORATE PURPOSES.  Full Article

Heron Therapeutics gets FDA approval for Cinvanti
Thursday, 9 Nov 2017 04:05pm EST 

Nov 9 (Reuters) - Heron Therapeutics Inc :Announces U.S. FDA approval of Cinvanti™ (aprepitant) injectable emulsion for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (cinv).U.S. Commercial launch of Cinvanti is planned for January 2018​.Remain on-track with htx-011 which we expect to file for FDA review in 2018​.  Full Article

Heron Therapeutics reports qtrly diluted net loss per share $0.77
Monday, 6 Nov 2017 08:30am EST 

Nov 6 (Reuters) - Heron Therapeutics Inc :Heron Therapeutics reports financial results for the three and nine months ended September 30, 2017 and recent corporate progress.Qtrly basic and diluted net loss per share $0.77‍​.Heron Therapeutics Inc - ‍net product sales of Sustol for three months ended September 30, 2017 were $8.6 million​.Heron Therapeutics Inc - ‍Heron's cash, cash equivalents and short-term investments were $74.0 million as of September 30, 2017​.Heron Therapeutics Inc - ‍guidance for full-year 2017 net product sales of Sustol remains $25 million to $30 million​.  Full Article

Heron Therapeutics granted FDA fast track designation for HTX-011
Thursday, 26 Oct 2017 08:30am EDT 

Oct 26 (Reuters) - Heron Therapeutics Inc :Heron Therapeutics granted FDA fast track designation for HTX-011 to reduce postoperative pain and the need for opioid analgesics for 72 hours.Heron Therapeutics Inc - ‍Phase 3 studies for HTX-011 ongoing; NDA filing planned for 2018​.Heron Therapeutics - ‍expect to report top-line results from pivotal phase 3 studies in first half of 2018 and file for FDA review in second half of 2018​.  Full Article

Heron Therapeutics reports quarterly loss per share $0.80
Wednesday, 9 Aug 2017 04:20pm EDT 

Aug 10 (Reuters) - Heron Therapeutics Inc -:Heron Therapeutics reports financial results for the three and six months ended June 30, 2017 and recent corporate progress.Quarterly loss per share $0.80.Heron Therapeutics Inc - ‍has increased its full year 2017 net product sales of sustol guidance to a range of $25 to $30 million​.Heron - ‍believes cash, cash equivalents and short-term investments provides co with funding sufficient to complete htx-011 phase 3 studies in h1 2018​.  Full Article

Heron Therapeutics initiates phase 3 program for HTX-011
Wednesday, 9 Aug 2017 04:05pm EDT 

Aug 9 (Reuters) - Heron Therapeutics Inc :Heron Therapeutics announces initiation of phase 3 program for HTX-011 in postoperative pain following successful end-of-phase 2 meeting with FDA.‍Phase 3 program expected to enable broad indication​.‍NDA filing planned for 2018​.‍FDA noted beyond agreed-upon phase 3 studies,no additional clinical work needed to meet "combination rule" for fixed-dose combination products​.  Full Article

Heron Therapeutics reports quarterly loss per share $1.00
Wednesday, 10 May 2017 08:00am EDT 

May 10 (Reuters) - Heron Therapeutics Inc : :Heron Therapeutics reports financial results for the three months ended March 31, 2017 and recent corporate progress.Quarterly loss per share $1.00.  Full Article

Heron Therapeutics appoints Robert Hoffman as CFO
Monday, 24 Apr 2017 04:05pm EDT 

April 24 (Reuters) - Heron Therapeutics Inc :Heron Therapeutics appoints Robert E. Hoffman as chief financial officer and senior vice president, finance.Heron Therapeutics Inc - prior to joining Heron, Hoffman served as executive vice president and chief financial officer of Innovus Pharmaceuticals.  Full Article

Heron Therapeutics says CEO Barry Quart named principal financial officer - SEC filing
Monday, 3 Apr 2017 11:20am EDT 

Heron Therapeutics Inc :In connection with Brian Drazba's departure, CEO Barry Quart assumed role of principal financial officer, effective April 1, 2017.  Full Article